Extension Study Confirms JAK Inhibitor's Activity in Atopic Dermatitis

(MedPage Today) -- The efficacy and safety of oral upadacitinib (Rinvoq) in patients with moderate to severe atopic dermatitis observed in two phase III randomized trials was maintained out to week 52 in a blinded extension study, researchers reported...